R
Renata Ferrarotto
Researcher at University of Texas MD Anderson Cancer Center
Publications - 205
Citations - 4472
Renata Ferrarotto is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 26, co-authored 167 publications receiving 2322 citations. Previous affiliations of Renata Ferrarotto include University of São Paulo & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Daniel J. McGrail,Patrick G. Pilie,Naim U. Rashid,Leonie Voorwerk,Maarten Slagter,Marleen Kok,Eric Jonasch,Mustafa Khasraw,Amy B. Heimberger,Bora Lim,NT Ueno,Jennifer K. Litton,Renata Ferrarotto,Jeffrey T. Chang,S. L. Moulder,Sy Lin +15 more
TL;DR: In this article, the authors compared approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells, and found that TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors.
Journal ArticleDOI
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
Erminia Massarelli,William N. William,Faye M. Johnson,Merrill S. Kies,Renata Ferrarotto,Ming Guo,Lei Feng,J. Jack Lee,Hai T. Tran,Young Uk Kim,Cara Haymaker,Chantale Bernatchez,Michael A. Curran,Tomas Zecchini Barrese,Jaime Rodriguez Canales,Ignacio I. Wistuba,Lerong Li,Jing Wang,Sjoerd H. van der Burg,Cornelis J. M. Melief,Bonnie S. Glisson +20 more
TL;DR: The overall response rate of 33% and median overall survival of 17.5 months is promising compared with PD-1 inhibition alone in similar patients, and a randomized clinical trial to confirm the contribution of HPV-16 vaccination to tumoricidal effects of PD- 1 inhibition is warranted for further study.
Journal ArticleDOI
Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors
Renata Ferrarotto,Yoshitsugu Mitani,Lixia Diao,Irene Guijarro,Jing Wang,Patrick A. Zweidler-McKay,Diana Bell,William N. William,Bonnie S. Glisson,Michael J. Wick,Ann M. Kapoun,Amita Patnaik,S. Gail Eckhardt,Pamela N. Munster,Leonardo Faoro,Jakob Dupont,J. Jack Lee,Andrew Futreal,Adel K. El-Naggar,John V. Heymach +19 more
TL;DR: Notch1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype, advanced-stage disease at diagnosis, higher rate of liver and bone metastasis, and shorter overall survival when compared with NOTCH1 wild-type tumors.
Journal ArticleDOI
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
Jennifer Wang,Mark Zafereo,Ramona Dadu,Renata Ferrarotto,Naifa L. Busaidy,Charles Lu,Salmaan Ahmed,Maria Gule-Monroe,Michelle D. Williams,Erich M. Sturgis,Ryan P. Goepfert,Neil D. Gross,Stephen Y. Lai,Gary Brandon Gunn,Jack Phan,David I. Rosenthal,Clifton D. Fuller,William H. Morrison,Priyanka C. Iyer,Maria E. Cabanillas +19 more
TL;DR: The first series in the literature of BRAFV600E-mutated ATC patients with locoregionally advanced disease treated with DT followed by surgical resection is reported, demonstrating feasibility of complete resection, decreased need for tracheostomy, high pathologic response rates, and durable Locoregional control with symptom amelioration.
Journal ArticleDOI
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer,Ramona Dadu,Maria Gule-Monroe,Naifa L. Busaidy,Renata Ferrarotto,Mouhammed Amir Habra,Mark Zafereo,Michelle D. Williams,G. Brandon Gunn,Horiana B. Grosu,Heath D. Skinner,Erich M. Sturgis,Neil D. Gross,Maria E. Cabanillas +13 more
TL;DR: In a subset of ATC patients, pembrolizumab may be an effective salvage therapy added to kinase inhibitors at the time of progression on these drugs, however, better treatment strategies aimed at incorporating immunotherapy in patients with ATC should be explored.